The antimicrobial peptide human cationic antimicrobial protein-18/ cathelicidin LL-37 as a putative growth factor for malignant melanoma

J. E. Kim, H. J. Kim, J. M. Choi, K. H. Lee, T. Y. Kim, B. K. Cho, J. Y. Jung, K. Y. Chung, Dae Ho Cho, H. J. Park

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background Recent evidence suggests cathelicidin LL-37 to be a growth factor for various human cancers such as lung cancer, ovarian cancer and breast cancer. However, the effect of LL-37 against malignant skin cancer has not been reported. Objectives To investigate whether the human cathelicidin LL-37 is involved in the carcinogenesis of various skin tumours. Methods Human cationic antimicrobial protein-18 (hCAP-18)/LL-37 production in several cell lines including HaCaT, a chronic myelogenous leukaemia (CML) cell line and various melanoma cell lines was examined using reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay. Immunohistochemical analysis of melanoma, nonmelanoma skin cancer and precancerous and benign skin lesions was performed. After adding LL-37 to a melanoma cell line, tumour cell proliferation, migration and invasion were investigated. Results Human malignant melanoma cell lines overexpressed hCAP-18/LL-37 mRNA and peptide compared with HaCaT and CML cell lines. Immunohistochemistry showed that the peptide was strongly expressed in malignant melanoma and moderately expressed in squamous cell carcinoma, whereas basal cell carcinoma, precancerous lesions and seborrhoeic keratosis showed no or weak expression. LL-37 also stimulated melanoma cell proliferation, migration and invasion in vitro. Conclusions Cathelicidin LL-37 was primarily expressed in human malignant skin cancer. LL-37 promoted melanoma cell proliferation, migration and invasion in vitro. We report that an increase in the level of LL-37 is associated with malignant skin tumours such as malignant melanoma. These results highlight the importance of LL-37 in the malignant tendency of skin tumours.

Original languageEnglish
Pages (from-to)959-967
Number of pages9
JournalBritish Journal of Dermatology
Volume163
Issue number5
DOIs
Publication statusPublished - 2010 Nov 1
Externally publishedYes

Fingerprint

Antimicrobial Cationic Peptides
Melanoma
Intercellular Signaling Peptides and Proteins
Proteins
Skin Neoplasms
Cell Line
Cell Movement
Skin
Cell Proliferation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms
Breast Neoplasms
Keratosis
CAP18 lipopolysaccharide-binding protein
Basal Cell Carcinoma
Tumor Cell Line
Ovarian Neoplasms
Reverse Transcription
Squamous Cell Carcinoma
Lung Neoplasms

Keywords

  • Antimicrobial peptide
  • LL-37
  • Malignant skin cancer
  • Melanoma
  • Skin tumours
  • Tumour progression

ASJC Scopus subject areas

  • Dermatology

Cite this

The antimicrobial peptide human cationic antimicrobial protein-18/ cathelicidin LL-37 as a putative growth factor for malignant melanoma. / Kim, J. E.; Kim, H. J.; Choi, J. M.; Lee, K. H.; Kim, T. Y.; Cho, B. K.; Jung, J. Y.; Chung, K. Y.; Cho, Dae Ho; Park, H. J.

In: British Journal of Dermatology, Vol. 163, No. 5, 01.11.2010, p. 959-967.

Research output: Contribution to journalArticle

Kim, J. E. ; Kim, H. J. ; Choi, J. M. ; Lee, K. H. ; Kim, T. Y. ; Cho, B. K. ; Jung, J. Y. ; Chung, K. Y. ; Cho, Dae Ho ; Park, H. J. / The antimicrobial peptide human cationic antimicrobial protein-18/ cathelicidin LL-37 as a putative growth factor for malignant melanoma. In: British Journal of Dermatology. 2010 ; Vol. 163, No. 5. pp. 959-967.
@article{107e554de1aa4ccbb46d514179b975c3,
title = "The antimicrobial peptide human cationic antimicrobial protein-18/ cathelicidin LL-37 as a putative growth factor for malignant melanoma",
abstract = "Background Recent evidence suggests cathelicidin LL-37 to be a growth factor for various human cancers such as lung cancer, ovarian cancer and breast cancer. However, the effect of LL-37 against malignant skin cancer has not been reported. Objectives To investigate whether the human cathelicidin LL-37 is involved in the carcinogenesis of various skin tumours. Methods Human cationic antimicrobial protein-18 (hCAP-18)/LL-37 production in several cell lines including HaCaT, a chronic myelogenous leukaemia (CML) cell line and various melanoma cell lines was examined using reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay. Immunohistochemical analysis of melanoma, nonmelanoma skin cancer and precancerous and benign skin lesions was performed. After adding LL-37 to a melanoma cell line, tumour cell proliferation, migration and invasion were investigated. Results Human malignant melanoma cell lines overexpressed hCAP-18/LL-37 mRNA and peptide compared with HaCaT and CML cell lines. Immunohistochemistry showed that the peptide was strongly expressed in malignant melanoma and moderately expressed in squamous cell carcinoma, whereas basal cell carcinoma, precancerous lesions and seborrhoeic keratosis showed no or weak expression. LL-37 also stimulated melanoma cell proliferation, migration and invasion in vitro. Conclusions Cathelicidin LL-37 was primarily expressed in human malignant skin cancer. LL-37 promoted melanoma cell proliferation, migration and invasion in vitro. We report that an increase in the level of LL-37 is associated with malignant skin tumours such as malignant melanoma. These results highlight the importance of LL-37 in the malignant tendency of skin tumours.",
keywords = "Antimicrobial peptide, LL-37, Malignant skin cancer, Melanoma, Skin tumours, Tumour progression",
author = "Kim, {J. E.} and Kim, {H. J.} and Choi, {J. M.} and Lee, {K. H.} and Kim, {T. Y.} and Cho, {B. K.} and Jung, {J. Y.} and Chung, {K. Y.} and Cho, {Dae Ho} and Park, {H. J.}",
year = "2010",
month = "11",
day = "1",
doi = "10.1111/j.1365-2133.2010.09957.x",
language = "English",
volume = "163",
pages = "959--967",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - The antimicrobial peptide human cationic antimicrobial protein-18/ cathelicidin LL-37 as a putative growth factor for malignant melanoma

AU - Kim, J. E.

AU - Kim, H. J.

AU - Choi, J. M.

AU - Lee, K. H.

AU - Kim, T. Y.

AU - Cho, B. K.

AU - Jung, J. Y.

AU - Chung, K. Y.

AU - Cho, Dae Ho

AU - Park, H. J.

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Background Recent evidence suggests cathelicidin LL-37 to be a growth factor for various human cancers such as lung cancer, ovarian cancer and breast cancer. However, the effect of LL-37 against malignant skin cancer has not been reported. Objectives To investigate whether the human cathelicidin LL-37 is involved in the carcinogenesis of various skin tumours. Methods Human cationic antimicrobial protein-18 (hCAP-18)/LL-37 production in several cell lines including HaCaT, a chronic myelogenous leukaemia (CML) cell line and various melanoma cell lines was examined using reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay. Immunohistochemical analysis of melanoma, nonmelanoma skin cancer and precancerous and benign skin lesions was performed. After adding LL-37 to a melanoma cell line, tumour cell proliferation, migration and invasion were investigated. Results Human malignant melanoma cell lines overexpressed hCAP-18/LL-37 mRNA and peptide compared with HaCaT and CML cell lines. Immunohistochemistry showed that the peptide was strongly expressed in malignant melanoma and moderately expressed in squamous cell carcinoma, whereas basal cell carcinoma, precancerous lesions and seborrhoeic keratosis showed no or weak expression. LL-37 also stimulated melanoma cell proliferation, migration and invasion in vitro. Conclusions Cathelicidin LL-37 was primarily expressed in human malignant skin cancer. LL-37 promoted melanoma cell proliferation, migration and invasion in vitro. We report that an increase in the level of LL-37 is associated with malignant skin tumours such as malignant melanoma. These results highlight the importance of LL-37 in the malignant tendency of skin tumours.

AB - Background Recent evidence suggests cathelicidin LL-37 to be a growth factor for various human cancers such as lung cancer, ovarian cancer and breast cancer. However, the effect of LL-37 against malignant skin cancer has not been reported. Objectives To investigate whether the human cathelicidin LL-37 is involved in the carcinogenesis of various skin tumours. Methods Human cationic antimicrobial protein-18 (hCAP-18)/LL-37 production in several cell lines including HaCaT, a chronic myelogenous leukaemia (CML) cell line and various melanoma cell lines was examined using reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay. Immunohistochemical analysis of melanoma, nonmelanoma skin cancer and precancerous and benign skin lesions was performed. After adding LL-37 to a melanoma cell line, tumour cell proliferation, migration and invasion were investigated. Results Human malignant melanoma cell lines overexpressed hCAP-18/LL-37 mRNA and peptide compared with HaCaT and CML cell lines. Immunohistochemistry showed that the peptide was strongly expressed in malignant melanoma and moderately expressed in squamous cell carcinoma, whereas basal cell carcinoma, precancerous lesions and seborrhoeic keratosis showed no or weak expression. LL-37 also stimulated melanoma cell proliferation, migration and invasion in vitro. Conclusions Cathelicidin LL-37 was primarily expressed in human malignant skin cancer. LL-37 promoted melanoma cell proliferation, migration and invasion in vitro. We report that an increase in the level of LL-37 is associated with malignant skin tumours such as malignant melanoma. These results highlight the importance of LL-37 in the malignant tendency of skin tumours.

KW - Antimicrobial peptide

KW - LL-37

KW - Malignant skin cancer

KW - Melanoma

KW - Skin tumours

KW - Tumour progression

UR - http://www.scopus.com/inward/record.url?scp=78249268522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78249268522&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2133.2010.09957.x

DO - 10.1111/j.1365-2133.2010.09957.x

M3 - Article

VL - 163

SP - 959

EP - 967

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 5

ER -